Back to Newsroom
Back to Newsroom

Reminder Bronstein, Gewirtz & Grossman, LLC Class Action: BPI, CRBP & NIO

Wednesday, 08 May 2019 10:32 AM

Bronstein, Gewirtz and Grossman, LLC

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bridgepoint Education, Inc. (NYSE: BPI)
Class Period:March 8, 2016 - March 7, 2019,
Deadline: May 10, 2019
For more info: www.bgandg.com/bpi

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Bridgepoint's processes for recording revenue for its FTG program were inaccurate; (2) Bridgepoint maintained deficient internal controls; (3) due to the foregoing deficiencies, Bridgepoint was prone to and did commit material accounting errors related to revenue, provision for bad debts, accounts receivable and deferred revenue, which resulted in the overstatement of revenue and expenses; and (4) as a result, Bridgepoint's public statements were materially false and misleading at all relevant times.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
Class Period:
November 14, 2016 - February 28, 2019
Deadline: May 13, 2019
For more info :www.bgandg.com/crbp

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

NIO Inc. (NYSE: NIO)
Class Period: September 12, 2018 - March 5, 2019
Deadline:
May 13, 2019
For more info:
www.bgandg.com/nio

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on a little-known Chinese state-owned auto manufacturer, JAC Auto, to manufacture its electric vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO's sales; and (3) as a result, defendants' statements about NIO's business, operations, and prospects were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Topic:
Advertorial
Back to newsroom
Back to Newsroom
Share by: